| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) (NCT05458297) | Merck Sharp & Dohme LLC | 2022-07-21 |
| Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma (NCT04792502) | Brown University | 2022-07-14 |
| A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (NCT05444322) | He Huang | 2022-07-05 |
| Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy (NCT05255354) | Adaptive Biotechnologies | 2022-06-01 |
| A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma (NCT05389293) | Memorial Sloan Kettering Cancer Center | 2022-05-27 |
| Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy (NCT05414162) | University Hospital, Bonn | 2022-05-16 |
| Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader (NCT05294731) | BeiGene | 2022-05-06 |
| Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma (NCT05326308) | iOMEDICO AG | 2022-04-26 |
| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia (NCT05281809) | John Lister | 2022-04-19 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies (NCT05107856) | Prelude Therapeutics | 2022-03-22 |
| Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma (NCT03361852) | Dana-Farber Cancer Institute | 2022-03-14 |
| Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy (NCT05064787) | Pack Health | 2022-03-11 |
| A Phase II Trial of Intermediate Radiation Dose For Lymphoma (NCT05284825) | Sunnybrook Health Sciences Centre | 2022-02-28 |
| Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy (NCT06782854) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2022-02-21 |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL (NCT05176691) | Hutchmed | 2022-02-15 |
| Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma (NCT04998669) | Juan P. Alderuccio, MD | 2022-02-11 |
| Study of Copanlisib and Ketogenic Diet (NCT04750941) | Columbia University | 2022-02-10 |
| Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies (NCT04599634) | National Cancer Institute (NCI) | 2021-12-16 |
| Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma (NCT05058404) | Fondazione Italiana Linfomi - ETS | 2021-12-01 |
| PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies (NCT05003141) | Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | 2021-11-15 |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (NCT05006716) | BeOne Medicines | 2021-09-13 |
| A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma (NCT04722601) | University of Chicago | 2021-09-01 |
| Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (NCT04962126) | Olivia Newton-John Cancer Research Institute | 2021-08-17 |
| Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (NCT04491370) | New York Medical College | 2021-08-01 |
| Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) (NCT04989621) | Sun Yat-sen University | 2021-08-01 |
| Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. (NCT04775745) | Newave Pharmaceutical Inc | 2021-07-19 |
| A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (NCT04669171) | Enterome | 2021-07-05 |
| Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma (NCT02194751) | XEME Biopharma Inc. | 2021-07-01 |
| Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell (NCT05784415) | AIDS Malignancy Consortium | 2021-05-22 |
| Efficacy of COVID-19 Vaccination in Patientstreated With Anti-CD20 for Follicular Lymphoma or Mantle Cell Lymphoma (NCT04918940) | Centre Henri Becquerel | 2021-05-21 |
| First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies (NCT04763083) | NovalGen Ltd. | 2021-05-14 |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia (NCT04806035) | TG Therapeutics, Inc. | 2021-04-28 |
| A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (NCT04680052) | Incyte Corporation | 2021-04-15 |
| Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma (NCT04849351) | Hutchison Medipharma Limited | 2021-04-15 |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients (NCT04858568) | University Hospital Southampton NHS Foundation Trust | 2021-03-11 |
| RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies (NCT04844086) | Eden BioCell Ltd. | 2021-03-02 |
| A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (NCT04594642) | AstraZeneca | 2021-03-02 |
| Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study (NCT04842318) | Ruijin Hospital | 2021-03-01 |
| Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region (NCT04859920) | Centre Hospitalier Universitaire Dijon | 2021-03-01 |
| Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy (NCT04745559) | H. Lee Moffitt Cancer Center and Research Institute | 2021-02-18 |
| A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma (NCT04379167) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2020-12-30 |
| SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma (NCT04762160) | Epizyme, Inc. | 2020-12-15 |
| Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity (NCT04503538) | Wake Forest University Health Sciences | 2020-12-01 |
| Study of LUCAR-20S in Patients With R/R NHL (NCT04176913) | The First Affiliated Hospital with Nanjing Medical University | 2020-12-01 |
| Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma (NCT04508647) | University of Colorado, Denver | 2020-11-23 |
| Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (NCT04223765) | UNC Lineberger Comprehensive Cancer Center | 2020-11-12 |
| A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (NCT04072458) | Bio-Path Holdings, Inc. | 2020-11-05 |
| Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (NCT04663347) | Genmab | 2020-11-03 |
| A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden (NCT05387616) | Ludwig-Maximilians - University of Munich | 2020-10-19 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (NCT04545762) | C. Babis Andreadis | 2020-09-11 |
| Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) (NCT04542824) | Genmab | 2020-08-20 |
| Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma (NCT04468841) | Memorial Sloan Kettering Cancer Center | 2020-07-08 |
| A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. (NCT04224493) | Epizyme, Inc. | 2020-06-11 |
| CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520) | Medical College of Wisconsin | 2020-05-18 |
| Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (NCT04282018) | BeiGene | 2020-04-29 |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas (NCT04305444) | Zhejiang DTRM Biopharma | 2020-04-24 |
| Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL (NCT04342117) | SecuraBio | 2020-04-23 |
| BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) (NCT04018248) | Boryung Pharmaceutical Co., Ltd | 2020-04-21 |
| TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT04323657) | TCR2 Therapeutics | 2020-03-27 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (NCT03842696) | University of Michigan Rogel Cancer Center | 2020-02-04 |
| Adjustment of Chemotherapy Duration in Follicular Lymphoma According to Minimal Residual Disease Status (NCT04934930) | Meir Medical Center | 2020-01-29 |
| A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma (NCT04707079) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2019-12-18 |
| Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI (NCT04154228) | Tel-Aviv Sourasky Medical Center | 2019-12-10 |
| Italian Observational Study on CAR-T Therapy for Lymphoma (NCT06339255) | Paolo Corradini | 2019-10-30 |
| Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma (NCT03890289) | Fondazione Italiana Linfomi - ETS | 2019-10-18 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (NCT03997968) | Cyteir Therapeutics, Inc. | 2019-10-09 |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (NCT04082936) | IGM Biosciences, Inc. | 2019-09-30 |
| Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN) (NCT04034056) | Hoffmann-La Roche | 2019-09-02 |
| Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma (NCT03919175) | Massachusetts General Hospital | 2019-09-01 |
| Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma (NCT03789240) | National Cancer Institute (NCI) | 2019-08-22 |
| Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma (NCT03980171) | Peter MacCallum Cancer Centre, Australia | 2019-08-19 |
| Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma (NCT03828448) | TG Therapeutics, Inc. | 2019-07-10 |
| Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea (NCT04048395) | Samsung Medical Center | 2019-07-08 |
| CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma (NCT04089215) | Shanghai Ming Ju Biotechnology Co., Ltd. | 2019-06-11 |
| Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry (NCT04587388) | European Hematology Association - Lymphoma Group | 2019-05-22 |
| Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (NCT03976102) | Dr. Reddy's Laboratories Limited | 2019-05-15 |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) (NCT03833180) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2019-03-14 |
| Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma (NCT03884998) | City of Hope Medical Center | 2019-02-26 |
| Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma (NCT03685344) | ADC Therapeutics S.A. | 2019-02-04 |
| A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies (NCT03999697) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2018-12-01 |
| Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma. (NCT03720457) | Hrain Biotechnology Co., Ltd. | 2018-11-13 |
| Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (NCT03568461) | Novartis Pharmaceuticals | 2018-11-12 |
| A Trial of Radiotherapy and Durvalumab in DLBCL and FL (NCT03610061) | Austin Health | 2018-11-01 |
| R2 in the Treatment of Follicular Lymphoma (NCT03715309) | Ruijin Hospital | 2018-11-01 |
| Rituximab + Immunotherapy in Follicular Lymphoma (NCT03636503) | Dana-Farber Cancer Institute | 2018-10-30 |
| Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL (NCT03806179) | Nordic Nanovector | 2018-10-04 |
| A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma (NCT03585725) | Weill Medical College of Cornell University | 2018-09-26 |
| Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR (NCT03676504) | University Hospital Heidelberg | 2018-09-07 |
| Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (NCT03600441) | Xynomic Pharmaceuticals, Inc. | 2018-08-27 |
| Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies (NCT03151057) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-07-31 |
| Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors (NCT03010982) | Epizyme, Inc. | 2018-06-20 |
| Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma (NCT03501576) | Emory University | 2018-04-06 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (NCT03314974) | Masonic Cancer Center, University of Minnesota | 2018-03-30 |
| Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia (NCT03374137) | Hoffmann-La Roche | 2018-03-09 |
| A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma (NCT03221348) | Cho Pharma Inc. | 2018-03-01 |
| Personalized Risk Stratification Model of Follicular Lymphoma Patients (NCT03436602) | Oncology Institute of Southern Switzerland | 2018-03-01 |
| Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies (NCT03424603) | Sutro Biopharma, Inc. | 2018-02-22 |
| Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product (NCT03436771) | Juno Therapeutics, a Subsidiary of Celgene | 2018-02-19 |
| Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas (NCT03276468) | The Lymphoma Academic Research Organisation | 2018-02-12 |
| The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies (NCT04184414) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2018-01-09 |